Keywords
How to Cite
Abstract
Migren profilaktikasida davolashga javob individual jihatdan sezilarli farq qiladi. Ushbu tezisda klinik fenotip, kasallik yuklamasi, psixoemotsional holat va kognitiv-ijro funksiyalarining profilaktik terapiya samaradorligini prognozlashdagi o‘rni tahlil qilindi. Zamonaviy ilmiy ma’lumotlarga ko‘ra, bir tomonlama og‘riq, kranial vegetativ belgilar, triptanlarga yaxshi javob va nisbatan past bazaviy kasallik yuklamasi ayrim CGRP yo‘naltirilgan davolash usullariga ijobiy javob bilan bog‘liq bo‘lishi mumkin.
References
1. Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333-341. doi:10.1111/head.14692.
2. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23:67. doi:10.1186/s10194-022-01431-x.
3. Barbanti P, Egeo G, Aurilia C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138. doi:10.1186/s10194-022-01498-6.
4. Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry. 2024;95(10):927-937. doi:10.1136/jnnp-2023-333295.
5. Braganza DL, Fitzpatrick LE, Nguyen ML, Crowe SF. Interictal cognitive deficits in migraine sufferers: a meta-analysis. Neuropsychol Rev. 2022;32(4):736-757. doi:10.1007/s11065-021 09516-1.
